UHE-105
DrugTopical shampoo containing active drug
NCT Number: NCT04243486
This study is to compare the safety and efficacy of UHE-105 Shampoo with that of the vehicle (VEH) Shampoo in subjects with scalp psoriasis. Half of the subjects will receive the UHE-105 Shampoo, while the other half will receive the VEH Shampoo with no active drug.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
01, San Diego, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other protocol defined inclusion or exclusion criteria assessed by the study staff may apply.
Topical shampoo containing active drug
Topical shampoo containing no active drug
Time frame: Day 15
The percentage of subjects classified as IGA treatment success
Time frame: Day 29
The percentage of subjects classified as IGA treatment success
Time frame: Days 8, 15, and 29
Percentage of subjects classified as treatment success for each of the clinical signs of psoriasis (scaling, erythema and plaque elevation)
Time frame: Days 8, 15, and 29
Change from baseline in the percentage of scalp affected by psoriasis
Time frame: Days 8, 15, and 29
Percentage of subjects classified as treatment success for change from baseline in pruritus severity score using an 11-point numeric rating scale (0-10)
Therapeutics, Inc.
Industry
A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05272150
Plaque Psoriasis, Scalp Psoriasis
Birmingham, Alabama, United States
View Trial DetailsNCT06771648
Scalp Psoriasis
Mölndal, Sweden
View Trial DetailsNCT05969223
Genital Psoriasis, Psoriasis
Phoenix, Arizona, United States
View Trial DetailsNCT05028582
Scalp Psoriasis
Scottsdale, Arizona, United States
View Trial Details